Feb 20 (Reuters) - Pfizer ( PFE ) will end global
development of its bleeding disorder gene therapy, Beqvez, the
Nikkei reported on Thursday.
Beqvez was approved in the U.S. last year, for the treatment
of adults with moderate to severe hemophilia B.